Respiratory Diseases
2025 Activity indicators
- 1 European project: MORPHEUS (HE)
- 3 competitive national public projects: ISCIII
- 2 private projects led
- 15 clinical studies led
- 2 competitive HR contracts
- 58 publications
- Impact Factor: 375.50
- Publications in Q1: 32 (55%)
- Publications in D1: 21 (36%)
- 1 doctoral thesis supervised and defended
- 3 awards
- Reviewers of projects and scientific papers: 1 PI
- Member of editorial boards: 1 PI
Milestones
- Publication in the world's leading cardiology journal: Jiménez D, Dubois-Silva Á, Demelo-Rodríguez P, Ruiz-Artacho P, López-Núñez JJ, Moisés J, Muriel A, Bura-Riviere A, Mahé I, Barillari G, Bikdeli B, Monreal M; RIETE Investigators. Acute pulmonary embolism: a multimarker calculator to predict short-term outcomes. Eur Heart J. Dec. 1, 2025;46(45):4921-4929.
- Award for Best Presentation at the Spanish Sleep Society Congress: "Long-term conditioning response following withdrawal of positional therapy in obstructive sleep apnea: a clinical trial."
- IRYCIS Young Talent: Dr. Esther Barbero: Awarded her first competitive public research grant under the AES25 call (PI25/00189), "Validation of a simple score to identify the sickest normotensive patients with acute symptomatic pulmonary embolism."
- Second national recruiting center in the CASSANDRA study (lung cancer screening in at-risk populations), funded by the Spanish Lung Foundation. SEPARIP: Dr. Rosa Mirambeaux.
- International coordination of the clinical trial initiated by ROPE researchers: "Registry-based randomized trial to determine the role of oxygen in acute pulmonary embolism."
Bibliometrics
| Articles | Accum. IF | Mean IF | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
|---|---|---|---|---|---|---|---|
| 2021 | 51 | 497.78 | 9.76 | 58 | 114 | 13 | 25 |
| 2022 | 50 | 490.70 | 9.81 | 46 | 92 | 15 | 30 |
| 2023 | 37 | 281.11 | 7.60 | 31 | 84 | 4 | 11 |
| 2024 | 54 | 374.30 | 6.93 | 43 | 80 | 21 | 39 |
| 2025 | 58 | 373,50 | 8,89 | 41 | 71 | 21 | 36 |
| 250 | 2017.39 | 8.60 | 204 | 82 | 74 | 28 |
*Only original articles, editorials, guidelines and reviews